195 related articles for article (PubMed ID: 22902447)
21. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
22. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
[TBL] [Abstract][Full Text] [Related]
23. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.
Ho CL; Su WC; Hsieh RK; Lin ZZ; Chao TY
Jpn J Clin Oncol; 2010 Apr; 40(4):294-301. PubMed ID: 20026457
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
[TBL] [Abstract][Full Text] [Related]
26. Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.
Uchida M; Mori Y; Nakamura T; Kato K; Kamezaki K; Takenaka K; Shiratsuchi M; Kadoyama K; Miyamoto T; Akashi K
Biol Pharm Bull; 2017; 40(9):1499-1505. PubMed ID: 28867732
[TBL] [Abstract][Full Text] [Related]
27. [A randomized cross-over comparative study of granisetron alone and combination of granisetron, methylprednisolone and droperidol as antiemetic prophilaxis in CDDP-based chemotherapy for gynecologic cancer].
Wataba K; Sagae S; Fukunaka N; Sugimura M; Akutagawa N; Hayashi T; Yamana K; Nakamura T; Terasawa K; Mizumoto H; Kitajima Y; Kudo R
Gan To Kagaku Ryoho; 1997 Apr; 24(6):691-7. PubMed ID: 9126306
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy of the granisetron/solumedrol combination in the control of drug-induced acute nausea and vomiting. Results of a prospective survey].
Debrix I; Puteaux S; Milleron B; Becker A
Ann Pharm Fr; 1995; 53(4):170-5. PubMed ID: 7574271
[TBL] [Abstract][Full Text] [Related]
29. [Granisetron oral phase III clinical trial--study on the inhibitory effect of granisetron for nausea/vomiting induced by chemotherapy for tumors in the hematopoietic organs].
Hiraoka A; Masaoka T; Nagai K; Kakishita E; Oshiba S; Kageyama T; Okuda K; Tatsumi N; Uchino H; Matsuzawa Y
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1835-41. PubMed ID: 8397489
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
31. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
32. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
33. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
34. [Therapeutic potential of Granisetron (Kitryl) for the prevention of nausea and vomiting induced by cytostatic drugs].
Gershanovich ML; Beresneva IA
Vopr Onkol; 1998; 44(2):225-8. PubMed ID: 9615833
[TBL] [Abstract][Full Text] [Related]
35. Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia.
Ono A; Kishimoto K; Hasegawa D; Goldman RD; Kosaka Y
Support Care Cancer; 2019 Mar; 27(3):895-899. PubMed ID: 30066198
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
37. Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer.
Abali H; Oyan B; Guler N
Chemotherapy; 2005 Aug; 51(5):280-5. PubMed ID: 16103667
[TBL] [Abstract][Full Text] [Related]
38. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
39. [Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation].
Park Y; Hatano Y; Sasamoto S; Kato N; Okuyama N; Yamazaki S
Gan To Kagaku Ryoho; 1997 Mar; 24(5):573-7. PubMed ID: 9087290
[TBL] [Abstract][Full Text] [Related]
40. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
